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Introduction: Infection with Epstein-Barr virus (EBV) has been suggested to contribute to the pathogenesis of
autoimmune diseases, including rheumatoid arthritis (RA). We sought to determine whether prior infection with the
virus occurs more frequently in patients with RA compared to controls.
Methods: We performed a systematic review and meta-analyses of studies that reported the prevalence of anti-EBV
antibodies in the sera of cases with RA and controls by searching Medline and Embase databases from 1946 to
2014, with no language restriction. Mantel-Haenszel odds ratios for the detection of anti-EBV antibodies were
calculated, and meta-analyses conducted. Quality assessments were performed using a modified version of the
Newcastle-Ottawa scale.
Results: Twenty-three studies were included. Quality assessment found most studies reported acceptable selection
criteria but poor descriptions of how cases and controls were recruited. When all studies were included, there was
a statistically significant higher seroprevalence of anti-VCA IgG in patients with RA compared to controls with an
odds ratio (OR) of 1.61 (95 % confidence interval (CI) 1.05–2.46, p = 0.03), which is a similar-sized summary OR to
that reported for systemic lupus erythematosus (SLE). However, when studies were restricted to those reporting
more plausible levels of exposure to EBV in the control groups, no significant association was apparent, OR 1.47
(95 % CI 0.88–2.46, p = 0.14). Using anti-EBNA 1 or anti-EA IgG as markers of previous infection also did not yield
significant associations (OR 1.05, 95 % CI 0.68–1.61, p = 0.82; OR 2.2, 95 % CI 0.86–5.65, p = 0.10 respectively).
Conclusions: Overall, these findings do not demonstrate an association between EBV seroprevalence and RA and
therefore do not support the hypothesis that prior infection with EBV predisposes to the development of RA. This
contrasts with meta-analyses that indicate EBV infection is associated with multiple sclerosis and SLE.Introduction
The causes of rheumatoid arthritis (RA) remain uncer-
tain. Several genetic loci involved in immune responses
have been identified [1], but environmental determinants
have been harder to identify. An increased risk in
cigarette smokers [2] represents the only generally ac-
cepted such factor [3]. Claims that prior infection with
Epstein-Barr virus (EBV) is important are of particular
interest, as an association has been repeatedly demon-
strated for multiple sclerosis (MS) [4] and a recent* Correspondence: m.a.vickers@abdn.ac.uk
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systemic lupus erythematosus (SLE) [5].
Control of EBV infection has been suggested to be im-
paired in RA patients [6] with studies using real-time
polymerase chain reaction (rt-PCR) techniques demon-
strating EBV DNA loads in peripheral blood mononuclear
cells greater than ten times those of normal controls [7].
EBV has been hypothesised to cause RA through several
mechanisms. Most notable is molecular mimicry, which
was first suggested following the identification of serum
from RA patients exhibiting reactivity against a nuclear
antigen in EBV-infected lymphocytes, called the RA nu-
clear antigen (RANA) [8]. A second example of molecular
mimicry was shown between the QKRAA amino acid
motif of the β-chain of HLA-DR4 and EBV glycoproteindistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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production of antibodies to gp110, which were demon-
strated in vitro to bind to HLA-DR4 [9]. Additional cross-
reactivity has been shown between the EBV peptide p107
and anti-denatured collagen and anti-keratin antibodies
[10]. Synovial T cells from RA patients have been shown
to recognise and be activated by peptides from the EBV
transactivators (MZLF1 and BMFL1) [11]. In addition to
molecular mimicry, suggested mechanisms for EBV caus-
ing immune-mediated disease [12] include mistaken self
[13], bystander damage surrounding EBV reactivation
[14], immortalisation of B cells secreting self-reactive anti-
bodies [15] and the resetting of the immune system to
favour more active global immunity against, with corres-
pondingly less tolerance to, antigens [16].
Laboratory identification of EBV infection typically re-
lies on detecting antibodies to EBV antigens, which in-
clude: EBV nuclear antigen (EBNA) -1, viral capsid
antigen (VCA), early antigen complex-diffuse (EA-D)
and early antigen complex-restricted (EA-R). Antibodies
to these EBV antigens can be utilised to identify the
stage of EBV infection. Antibodies to EA are thought to
indicate active EBV replication, whereas antibodies to
EBNA-1 and VCA persist for the life of the host.
Several researchers have reported higher proportions
of patients with RA having antibodies to EBV than con-
trols. However, these studies have been limited by small
sample sizes and have been contradicted by other studies
reporting no association. To date the authors are aware
of no systematic reviews examining the association be-
tween RA and previous infection with EBV. We and
others have previously reported systematic reviews dem-
onstrating significant associations between the presence
of antibodies to EBV and both MS [4] and SLE [5]. How-
ever, it is uncertain whether this association applies to
other immune-mediated diseases. In this study we
present the first systematic review and meta-analysis of
seropositivity for EBV among RA patients compared to
controls.
Methods
Search strategy
The Ovid search tool was used to explore Medline and
EMBASE databases with a structured use of MeSH and
Emtree headings for RA and EBV (Additional file 1). A
search was performed from 1946 to week 1 December
2014 in Medline and from 1984 to week 1 December
2014 in EMBASE. No restrictions were made to language
or country of study origin. Cohort or case–control studies
were included in this systematic review, which recruited
patients and controls of any age with RA and reported
antibodies to any of the following EBV antigens: VCA (viral
capsid antibody), EA (early antigen), EBNA (Epstein-Barr
virus nuclear antigen) -1 or -2. Non-human studies wereexcluded, as were those reporting only immunoglobulin M
(IgM) antibodies.
One reviewer read the abstracts and selected those for
full text examination (Fig. 1). Full texts of these articles
were read, with those meeting the inclusion criteria con-
sidered for data extraction. Authors were contacted
when data were not fully available. A selection of 200
abstracts from the Medline search were reviewed by a
second reviewer to examine for inter-reviewer variation,
with those for which full texts that should be sought and
those likely to be eligible for inclusion highlighted.
Quality assessment
Included studies were evaluated using the Newcastle-
Ottawa assessment scale [17], which was adapted to
offer one star for conducting the analysis in a clinical
laboratory (away from investigators), one star for men-
tioning explicit laboratory cutoffs for seropositivity and
one star for reporting whether or not there were missing
data.
Data analysis
Two of the authors independently extracted data from
each included study and any differences were discussed,
and resolved by discussion. One native speaker extracted
data from the Turkish [18] and Chinese [19] articles.
The odds ratios (ORs) of seropositivity to EBV were cal-
culated for each of the anti-EBV antibodies using Review
Manager (RevMan version 5.2. Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2012).
Odds ratios for each antibody were combined in a meta-
analysis. As we anticipated considerable study hetero-
geneity, we utilised a conservative random-effects model
with a 95 % confidence interval (CI). I2 was used to
assess heterogeneity between studies [20].
Post hoc subgroup analysis testing was performed to
compare the OR of VCA seropositivity in the following
categories to investigate potential sources of heterogen-
eity: studies with greater than 80 % VCA seropositivity
in the control group; studies with both age- and sex-
matched controls and studies with community controls.
Results
Following removal of duplicates, the search produced
2482 abstracts, from which 67 were considered for inclu-
sion and full texts accessed. A kappa statistic of agreement
(calculated using IBM SPSS Statistics for Windows, Version
22 of SPSS: IBM Corp, Armonk, NY, USA) was high at 87
% (p = <0.001). One author read each of the 67 articles,
with 40 meeting inclusion criteria, and these were read by
one of two additional authors for consideration. One
article was written in Chinese and one article in Turkish
with a single researcher reviewing each of these articles.
Four articles written in Russian were reviewed by
Fig. 1 Flow chart. Following removal of duplicates, the search produced 2482 abstracts and two articles were identified from references
of review articles. Sixty-seven were considered for inclusion and full texts accessed. Forty-four articles were excluded due to a number of
the following reasons: no seropositivity values (n = 9); no or inappropriate controls (n = 12); no EBV IgG or IgA data (n = 6); and non-RA
data (n = 2). Full results were not available for four articles and authors were contacted for available data, however, there were insufficient data provided
in each case and all were excluded. The remaining 23 studies were considered eligible for inclusion and are summarised in Additional file 2. EBV
Epstein-Barr virus, Ig immunoglobulin, RA rheumatoid arthritis
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teria due to a lack of appropriate controls (n = 2), no IgG-
specific data on EBV (n = 1) and data for leucocytes only
(n = 1). Two papers (Thomas et al. [21] and Alspaugh
et al. [22]) reported EBV VCA IgG as seropositive at ti-
tres <1/320 leading to low control group seropositivity
and so the authors excluded these two studies. In total
seventeen articles were excluded with agreement between
authors, leaving 23 articles for the meta-analysis (Fig. 1).
The 23 articles are summarised in Additional file 2 [6, 18,
19, 23–42]. All were case–control studies; no cohort studies
were identified. The median sample size for the disease
group was 50 (range 20–140) and 43 for the control group
(range 14–245). Quality assessment is provided in Table 1.
Three studies provided no diagnostic criteria for the
diagnosis of rheumatoid arthritis, while the remaining 20
utilised a form of either the American College of Rheuma-
tology (ACR) or American Rheumatology Association cri-
teria. The reported matching of controls was poor, with
only seven studies controlling for both age and sex, and
two controlling for age only. One study by Lunemann et al.
[24] reported sex matching: however, the presented demo-
graphics exhibited large disparities between control and
RA groups and so it was considered as not sex-matched.
The reporting of blinding of researchers was also poor,
with only one study blinding analysts to patient group.
Reporting of data was often unsatisfactory, with only nine
detailing the cutoff values for seropositivity (Table 1).Anti-viral capsid antigen IgG
Eighteen studies reported data on the presence of anti-
VCA IgG, including a total of 943 RA cases and 891controls, of which eight demonstrated higher rates of
seropositivity in RA patients compared to controls.
The summary OR demonstrated a statistically signifi-
cant increased seropositivity in RA patients compared
to controls with OR 1.61 (95 % CI 1.05–2.46, p = 0.03)
and I2 = 1 % (p = 0.44) (Figure S1 in Additional file 1).
However, on inspection of the data it was apparent
that one study (Saal et al. [25]) reported substantially
lower rates of antibody detection in both cases and con-
trols than the other studies and indeed, all the studies
included in previous studies of MS and SLE. On reread-
ing this article, no apparent cause was identified. We
consider these rates to be implausibly low and suspect that
there were problems in performance of the laboratory as-
says. Following exclusion of this article there was no sig-
nificant difference between RA patients and control group
EBV VCA IgG seroprevalences with OR 1.47 (95 % CI
0.88–2.46, p = 0.14) and I2 = 5 % (p = 0.40) (Fig. 2).
Including only studies with both age- and sex-matched
controls led to a significant difference for VCA IgG sero-
prevalence between RA patients and controls with OR
9.27 (95 % CI 1.64– 52.6, p = 0.01). However this analysis
was based on only six studies, although there was a low
degree of heterogeneity demonstrated (I2 = 0 %, p = 0.88)
(Figure S2 in Additional file 1). Restricting the analysis to
studies with community controls did not to lead to a
statistically significant difference with OR 2.02 (95 % CI
0.64–6.41, p = 0.23).Anti-Epstein-Barr virus nuclear antigen-1 IgG
Twelve studies reported anti-EBNA-1 serology, with a
total of 737 RA patients and 791 controls. Six studies
Table 1 Adapted Newcastle-Ottawa quality assessment
Study ID S1 S2 S3 S4 C1 C2 E1a E1b E2 E3
Ferrell and colleagues23 * - - - - - - - * -
Lunemann and colleagues24 * - * - * - - - * -
Saal and colleagues25 * - - - * - - * - -
Yazbek and colleagues26 * * - * * * - - * -
Mouzavi-Jazi and colleagues27 - - - * - - - - * -
Blaschke and colleagues28 * - * * * * - - * -
Venables and colleagues 198129 * - - - - - - * * -
Venables and colleagues 198530 * - - * - - - - * -
Sculley and colleagues31 * - * - - - - - * -
Shirodaria and colleagues32 * - - * * * - * * -
Silverman and colleagues33 * - - * * * - - * -
Ng and colleagues34 * - - - - - - - - -
Musiani and colleagues35 * - - * * * - * * -
Yao and colleagues36 * - - - * - - - * -
Philips and colleagues37 * - * * - - - - * -
Nakabayashi and colleagues38 * - - - * * - * - -
Us and colleagues18 * - * * * - - - * *
Youinou and colleagues39 * - * - - - - * * -
Draborg and colleagues40 * - - - - - - * * -
Jorgensen and colleagues41 * * * * * * - * * -
Zhang and colleagues 199919 * - * * - - * * * -
Zhang and colleagues 19936 * - * * - - - - * -
Davies and colleagues42 * - - - * - - - * -
Adapted Newcastle-Ottawa assessment scale. S1 objective case definition used, S2 cases consecutively recruited or obviously representative, S3 community controls,
S4 controls specified as having no history of disease, C1 age-matched control, C2 controls matched for additional factor, E1a conducting analysis in a clinical laboratory
(away from investigators), E1b explicit laboratory cutoffs for seropositivity mentioned, E2 same method of ascertainment for cases and controls, E3 missing data reported
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ever, there was no statistically significant difference
between cases of RA and controls with OR 1.05 (95 %
CI 0.68–1.61, p = 0.82). The samples showed a low level
of heterogeneity I2 = 26 % (p = 0.19) (Fig. 3).
Anti-early antigen IgG
Eight studies reported anti-early antigen (anti-EA)
serology, with 445 RA cases and 305 controls. A higher
degree of seropositivity was demonstrated in the RA
group compared to the controls. However this did not
reach statistical significance with an OR of 2.2 (95 % CI
0.86–5.65, p = 0.10) and the studies showed high
heterogeneity with I2 = 79 % (p = 0.0001) (Fig. 4).
Discussion
This meta-analysis of case–control studies investigating
the association between RA and serological markers of
EBV infection failed to show a significant association
between the disease and anti-VCA IgG (OR 1.47, 95 %
CI 0.88–2.46, p = 0.14), anti-EBNA1 IgG (OR 1.05, 95 %
CI 0.68–1.61, p = 0.82) or anti-EA (OR 2.2, 95 % CI0.86–5.65, p = 0.10). This analysis is, to our knowledge,
the first attempt to combine such estimates of associ-
ation with RA in a meta-analysis and should therefore
provide a more robust estimate of the association than
individual studies, which have tended to include rela-
tively small numbers of participants.
Strengths of this study include its comprehensive
search strategy, without language restriction. Conversely,
meta-analyses such as these are susceptible to publica-
tion bias, but there is no suggestion of this on a funnel
plot of those studies included in the anti-VCA. Of fur-
ther concern is the high level of heterogeneity between
the ORs of the individual studies, the lack of consistency
in matching of cases and controls, and the paucity of
reporting of recruitment and laboratory methodology, as
seen in the quality assessment. We attempted to control
for these factors by analysing only studies with commu-
nity controls; however, this limited the overall RA popu-
lation studied for VCA and EBNA-1 antibodies to
seven studies, with the results showing no difference
between seropositivity for these two groups. Thus fur-
ther examination of this topic with well-constructed,
Fig. 3 Forest plot for anti-EBNA-1 IgG. Random-effects meta-analysis of seroprevalence of anti-Epstein-Barr virus nuclear antigen-1 (EBNA-1)
immunoglobulin G (IgG) between rheumatoid arthritis cases and controls. CI confidence interval, M-H Mantel-Haenzsel, RA rheumatoid arthritis
Fig. 2 Forest plot for anti-VCA IgG excluding Saal et al. Random-effects meta-analysis of seroprevalence of anti-viral capsid antigen (VCA) immunoglobulin
G (IgG) between rheumatoid arthritis casesand controls excluding Saal et al. [25]. CI confidence interval, M-H Mantel-Haenzsel, RA rheumatoid arthritis
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Fig. 4 Forest plot for anti-EA IgG. Random-effects meta-analysis of seroprevalence of anti-early antigen (EA) immunoglobulin G (IgG) between
rheumatoid arthritis cases and. CI confidence interval, M-H Mantel-Haenzsel, RA rheumatoid arthritis
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determining whether EBV infection helps predispose
to RA. A further factor that might explain why
antibodies to EBV are detected more frequently in pa-
tients with RA compared to controls is that RA is an
inflammatory condition, with high concentrations of
immunoglobulins, including those directed against
EBV (Thomas et al. [21] and Alspaugh et al. [22]).
Thus failures to detect low titre antibodies would be
expected to occur more commonly in the control
groups, although the importance of this effect is difficult
to quantify. A further observation supporting our conclu-
sion of no association between RA and EBV is that the two
conditions do not occur together more often than that
expected by chance [43].
We hoped to find prospective studies that would allow
analysis of the relative timing of infection and the develop-
ment of RA, but our search revealed none. Nevertheless, in-
fection in the general population occurs generally below the
age of 20 [43] and so before the onset of symptoms of RA.
The results from this meta-analysis contrast with those
examining the role of EBV exposure in MS and SLE.
For MS, several meta-analyses have confirmed a robust
association, with summary odds ratios of approximately
4–5 [4]. Indeed, it has been suggested that the few
seronegative individuals arise because of low sensitivities
of the assays used to detect anti-EBV antibodies [44], with
enzyme-linked immunosorbent assays (ELISAs) perform-
ing worse than immunofluorescent techniques. Examin-
ation of our data shows no systematic difference in the
odds ratios reported by studies reporting the use of these
techniques (Additional file 2).
It is widely accepted that it is difficult to develop MS
unless infected by EBV. For SLE, we also reportedstatistically significant odds ratios for the detection of
antibodies to VCA (2.0) and EA in SLE, although that
for anti-EBNA1 did not reach significance [5]. Overall, it
seems likely that infection by EBV does predispose to
the development of SLE, but this conclusion should not
be regarded as proven.
If it is accepted that EBV plays an important role in
the pathogenesis of MS, probably SLE, but not RA,
what are the implications for the mechanisms that
underlie these associations? The most popular mech-
anism invoked to explain autoimmune disease after
infections is molecular mimicry, which is usually con-
ceived as a specific pathogen-immune disease pairings.
Our findings with RA are therefore consistent with
this mechanism. On the other hand, both the hypoth-
esis that EBV immortalises self-reactive B cells that
would otherwise be deleted [15] and the idea that
EBV resets the global immune system to a more active
state [16] imply that EBV infection should cause a
generic predisposition to autoimmune disease, which is
difficult to reconcile with the findings of the present
study. Two further mechanisms suggested to explain
the association are mistaken self [36] and bystander
damage surrounding EBV reactivation [14], both of
which are consistent with the disease associations be-
ing confined to specific diseases.
It should be highlighted that a lack of an association
between antibodies to EBV and RA does not preclude a
role for EBV in the disease as there are other lines of
evidence for this [45]. For instance, if the effect were
limited to only subtypes of disease or carriers of specific
genetic loci, for instance only particular HLA types, then
a causal association would not be identified by the num-
bers included in this meta-analysis.
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In summary, we performed a systematic review and meta-
analysis of studies reporting antibodies to EBV antigens in
patients with rheumatoid arthritis compared to controls.
There was no overall statistically significant association
between the presence of antibodies and the disease, but
most of the studies had limitations and further data are
needed.
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